Inflammation is nothing new for those who hit the gym regularly. When you work out your muscles, they get surrounded by blood as they try and heal. This inflammation can be painful, but fortunately there are ways to reduce the swelling and pain. Here are just a few ways to reduce or avoid inflammation after a hearty workout.
Ice It Down
When it comes to reducing swelling in the body, ice is the key. Having a cold temperature on the area helps to restrict the blood flow to your muscles. The trick is ensuring that you don’t spend too much time in the cold. It’s only recommended to do a maximum of 20 minutes with ice on a specific body part. After this time frame, your body will start to go into protective mode thinking that it’s getting frostbite. This will have an adverse effect that actually causes the body to purposefully cause inflammation in order to heat up. To avoid this, simply stick to 20 minutes maximum for any icing session.
Use A CBD Product
With the wide emergence of CBD in the United States market, more and more studies have been conducted on its overall health benefits. While many are still in the debating phase, one thing has been shown to be proven true about this substance. It works great for reducing inflammation in the body. You can get CBD into your bloodstream in multiple ways such as hemp CBD lotion, pills, edible gummies, and tinctures.
Get A Massage
When you find yourself in the hours after a tough workout, you want to do everything possible to reduce the amount of inflammation that your body undergoes. Getting a massage is one great way to alleviate muscle tension and allow blood to freely move throughout your body. You’ll want to pick the right type of massage to encourage healing and not induce inflammation. A Swedish massage is more preferred over other techniques like a deep-tissue massage.
Use Anti-Inflammatories
Anti-inflammatory medications can be utilized to reduce the amount of swelling that happens in your body and joints. These include over the counter medications like naproxen, ibuprofen, and aspirin. While these aren’t recommended for daily use, they can be extremely helpful when you’ve undergone a very rough workout.
Working out is a great way to keep your energy flowing and your body in shape. However, inflammation can put a real damper on your workout regimen. That is unless you utilize the tips outlined above to avoid post-workout inflammation so you can get back into the gym more often.
Brooke Chaplan is a freelance writer and blogger. She lives and works out of her home in Los Lunas, New Mexico. She loves the outdoors and spends most of her time hiking, biking, and gardening. For more information, contact Brooke via Facebook at facebook.com/brooke.chaplan or Twitter @BrookeChaplan
Pancreatic cancer - Promising Treatment for Deadly Cancer Blocked by Canadian Regulators
TORONTO, Aug. 19, 2020 /CNW Telbec/ - While innovations in health care are spurring extraordinary advances in the treatment of malignant tumours, progress has been limited when it comes to the world's toughest cancer. Pancreatic Cancer Canada is fighting to raise survival rates for pancreatic cancer patients through targeted investments in research, increased awareness and patient support, community activation and advocacy initiatives. Pancreatic cancer is the third leading cause of cancer-related deaths for Canadians in 2020. It has an exceptionally low five-year survival rate of just 8%. A diagnosis of pancreatic cancer means a 92% likelihood of death – a fact that has not changed significantly in over 40 years. Pancreatic cancer outcomes are worsening amid rising survival rates for most other cancers. Statistics show that 50% of those who are diagnosed with pancreatic cancer will die 4 months after diagnosis.
While new first-line treatments are becoming available to patients, disease progression after initial therapy is common, leaving patients with no options for further treatment, making it nearly impossible to halt the progression of this terrible cancer.
Significant therapeutic progress
In the modern era of cancer research, pancreatic cancer has proven to be among the most unyielding of adversaries. While advancements have been made in expanding our understanding of this cancer, the 5-year survival rate has not changed materially in the past 40 years, and nearly all diagnosed patients ultimately succumb to the diseasei.
Today, with positive results of a large Phase 3 clinical trial NAPOLI-1 with ONIVYDE (irinotecan liposome), some hope is possible. An innovative pancreatic cancer treatment, it has been shown to extend patients' overall survival by 45% while maintaining the quality of life for pancreatic cancer patients.
Onivyde is already funded in a number of countries and is recommended by the National Comprehensive Cancer Network's (NCCN) international guidelines. Onivyde has also recently received a fast-track designation from the US Food and Drug Administration (FDA) as a first-line combination treatment for metastatic pancreatic cancer.
An innovative treatment unavailable in Canada
In 2017, Health Canada granted regulatory approval of PrONIVYDE® (irinotecan liposome for injection) for the treatment of metastatic pancreatic cancer, in combination with standard chemotherapy medications, in adult patients who have disease progression following first-line treatment.
It is now more than three years later and this drug is still not available in Canada despite receiving positive recommendations from the pan-Canadian Oncology Drug Review (pCODR) and the Quebec Institut national d'excellence en santé et en services sociaux (INESSS).
Given the slow progress against this disease, one must ask the question, 'Why are our regulatory authorities waiting to fund the only new drug approved recently by Health Canada that has shown promise in pancreatic cancer?'
Pancreatic Cancer Canada (PCC), believes it is time for Canada to catch up to other countries in the treatment of pancreatic cancer and adds its voice to those of patients and doctors across the country who have already articulated their support for the funding of PrONIVYDE® directly with pCODR and INESSS, and continue to demand that this medication be reimbursed as soon as possible. We have a clear expectation that the pan-Canadian Pharmaceutical Alliance (pCPA) fulfill its mandate to negotiate drugs approved by Health Canada and to rapidly establish public funding across Canada.
Quotes
"Pancreatic Cancer Canada is very concerned by the delay in making approved medications for pancreatic cancer available to Canadians – delays that are costing patients their lives. We urgently request that provincial representatives on the negotiating committee amend their processes to prioritize the survival of pancreatic cancer patients over administrative needs. This system of delays and blocked access threatens to discourage critical research efforts, as well as significant investments by pharmaceutical companies who bring viable treatment options to our patients." Michelle Capobianco, Chief Executive Officer, Pancreatic Cancer Canada
"Canada needs to catch up with other industrialized countries and provide options for patients progressing from their first-line treatment. Introducing new treatment options in Québec would provide the oncology community with new tools to help patients continue in their fight against this devastating disease." Petr Kavan MD, PhD, Medical Oncologist, Segal Cancer Center Jewish General Hospital
"PrONIVYDE® offers patients a chance at better outcomes, through demonstrated efficacy in treating metastatic pancreatic cancer. There is a treatment within our reach to prolong the survival of patients without compromising their quality of life, and it's important that we make it accessible and without any further delay." Rebecca Prince, MBBS, FRACP, MSc, Medical Oncologist, University Health Network
"My husband did not live long enough to see a treatment developed that could save him. Pancreatic cancer patients today do not have the luxury of time. That is why we are asking for an end to the senseless delays in bringing promising drug treatments to the market. It is unbearable to know that there is an approved drug at our fingertips that could extend the lives of our loved ones – and yet, we can't access it. This is not how we will improve, and ultimately end, this deadly cancer." Joanne Furino, family caregiver
About Pancreatic Cancer Canada (PCC)
Pancreatic Cancer Canada is fighting to raise survival rates for the world's toughest cancer investing in targeted research, increased awareness and patient support, community activation and advocacy. We have taken on one of the world's deadliest cancers - a disease with virtually no progress in survival in the past 40 years and a 92% mortality rate. We are aggressively fighting it with investments in research aimed at greater understanding of this cancer and better treatment options. At the same time, we are working to educate physicians about faster diagnosis and with patients/families to support them as they face the realities of this cancer in their lives.
Alithya to Implement Oracle Cloud for Nemours Children's Health System
ALPHARETTA, GA, Aug. 19, 2020 /CNW Telbec/ - Alithya Group inc. (NASDAQ: ALYA) (TSX: ALYA) ("Alithya"), a leader in strategy and digital transformation employing more than 2,100 highly-qualified professionals and offering enterprise solutions throughout the United States, Canada, and Europe, has been selected by Nemours Children's Health System to support the implementation of Oracle Cloud for its finance and accounting, supply chain, human resource management, payroll, and reporting needs.
"We believe the combination of Oracle's world-class technology and Alithya's industry expertise will enable us to improve financial margins, optimize our health system for growth, and eliminate redundancy in systems and processes," stated Bernie Rice, Chief Information Officer and Enterprise Vice President at Nemours.
More than ever, the healthcare industry faces challenges and pressures unlike any other sector of the economy. As an Oracle Platinum Partner with a dedicated healthcare practice, Alithya supports Oracle solutions that provide the transparency and agility that healthcare organizations need to meet these new challenges head on.
"Alithya is proud to partner with Nemours for this project," said Russell Smith, President, Alithya USA. "Our multi-phased approach will effectively meet Nemours' business needs and demands by providing a core Human Capital Management (HCM) and Recruiting solution, a core Enterprise Resource Planning (ERP) system, and Enterprise Performance Management (EPM)."
About Nemours Children's Health System Nemours is an internationally recognized children's health system that owns and operates the two free-standing children's hospitals: the Nemours/Alfred I. du Pont Hospital for Children in Wilmington, Del., and Nemours Children's Hospital in Orlando, Fla., along with outpatient facilities in five states, delivering pediatric primary, specialty and urgent care. Nemours also powers the world's most-visited website for information on the health of children and teens, KidsHealth.org, and offers on-demand, online video patient visits through Nemours CareConnect.
About Alithya Alithya Group inc. is a leader in strategy and digital transformation in North America. Founded in 1992, the Company can count on more than 2,100 professionals in Canada, the US and Europe. Alithya's integrated offering is based on four pillars of expertise: strategy services, application services, enterprise solutions and data and analytics. Alithya deploys solutions, services, and skillsets to craft tools tailored to its clients' unique business needs in the Financial Services, Manufacturing, Energy, Telecommunications, Transportation and Logistics, Professional Services, Healthcare, and Government sectors. Corporate responsibility is at the heart of Alithya's management approach, and as such, the company is an advocate for good governance, workforce diversity and development, environment-friendly practices and social involvement in communities. To learn more, go to alithya.com.
SOURCE Alithya
Sunnybrook to lead suicide prevention research during COVID-19 pandemic with immediate investment from TELUS' CEO
TORONTO, ON, Aug. 19, 2020 /CNW/ - Critical research led by Sunnybrook Health Sciences Centre into suicide prevention during the COVID-19 pandemic is receiving an immediate $100,000 donation from TELUS President and CEO Darren Entwistle and the Entwistle Family Foundation. This timely support will enable researchers to identify factors that may influence suicide rates during the initial stages of the pandemic in order to help inform urgent prevention strategies that could help save lives.
Led by Dr. Mark Sinyor, suicide prevention expert and Sunnybrook psychiatrist, researchers will combine data from Toronto's three regional trauma centres: Sunnybrook, St. Michael's Hospital and the Hospital for Sick Children (SickKids). Data will include self-harm cases and suicide attempts over the first three months of the COVID-19 pandemic. The information will be analyzed to determine what drives risk for suicide during this pandemic and help guide prevention efforts, such as targeted outreach, mental health services, social assistance, and public messaging.
The COVID-19 pandemic is responsible for the sudden onset of a number of known stressors, including increased social isolation, economic insecurity and concerns about the virus itself. Dr. Sinyor and his team are working to more fully understand these and other triggers so that experts can intervene more effectively.
"Pandemics, such as COVID-19, can have a negative effect on mental health, which we know can influence suicide rates. At the same time, in crises like these, people can often come together, and this connection can help reduce suicide risk. The key point is that the effects of the pandemic are not the same for everyone," says Dr. Sinyor. "We are seeing signs that it is increasing the risk of suicide for some individuals. We have to work to understand this better to help inform hospital systems and mental health care providers of ways to adapt and provide further support, because suicide is preventable."
The research project is planned to continue through one year of the pandemic so that longer term trends and data can shape ongoing public policy related to COVID-19 and future public health emergencies.
"Suicide rates have been stable or even decreasing slightly in Canada over the past two decades, but they are still too high – every death is a tragedy – and we are certainly worried that the pandemic is creating the conditions that can push these rates in the wrong direction," says Dr. Sinyor. "This research will assist in implementing the most effective measures to help save lives across Canada and beyond."
Support from Darren Entwistle and the Entwistle Family Foundation will help Sunnybrook share this much-needed information with hospitals across Toronto and Canada, the Canadian Association for Suicide Prevention and international groups including the World Health Organization and International Association for Suicide Prevention.
Earlier this year, Mr. Entwistle committed the equivalent of three months' salary to critical COVID-19 research across Canada. Through this act of generosity, donations were made to BC Women's Hospital to support mental health programs, McGill University Health Centre Foundation to enable ICU patients to connect with loved ones, and Sunnybrook Foundation to urgently address suicide prevention needs.
This generous contribution from Mr. Entwistle and his family builds on a legacy of giving by TELUS, with more than $150 million dedicated to support Canadians through the pandemic and $1.3 billion in value, time and financial support to Canadian charities and grassroots organizations since 2000.
If you need help in an emergency please call 911 or visit your local emergency department. If you're feeling like you're in crisis or need somebody to talk to, please know that help is also available through community resources:
Teva Canada announces product availability of AJOVY™
AJOVY™ is the first and only anti-CGRP treatment with both quarterly and monthly dosing for the preventive treatment of migraine in adults
AJOVY™ is supported by the AJOVY™ Teva Support Solutions® (AJOVY TSS) Patient Support Program, whose services include reimbursement navigation, bridging/copay coverage, and injection training.
AJOVY™ has been studied in patients with chronic or episodic migraine and was shown to significantly reduce patients' mean monthly migraine days—with some patients achieving a 50% reduction or more.1–3
MONTRÉAL, Aug. 19, 2020 /CNW/ - Teva Canada, a subsidiary of Teva Pharmaceutical Industries Ltd., today announced product availability of AJOVY™ (fremanezumab) 225 mg solution for subcutaneous injection for the preventive treatment of migraine in adults who have at least four migraine days per month. AJOVY™ is the first and only anti-CGRP drug approved in Canada, the European Union, and the United States that offers quarterly or monthly dosing regimens for the preventive treatment of migraine. The quarterly dose of 675 mg is given as three 225 mg subcutaneous injections once every three months; the monthly dose of 225 mg is given as one subcutaneous injection once each month. AJOVY™ is currently available in a latex-free prefilled syringe.1–3
"Canadian patients and prescribers have been waiting for a product like AJOVY™ that offers flexible dosing options convenient for their busy lifestyles," says Christine Poulin, General Manager of Teva Canada. "With the product now in distribution across Canada, Teva Canada is also introducing a comprehensive patient support program to educate patients and provide financial support to meet the various needs of Canadians who suffer with the condition."
Migraine is a disabling chronic neurological disease that causes head pain so severe that sufferers often cannot function during an attack. Migraine reduces quality of life and disrupts migraineurs' ability to perform daily activities.4,5 It is among the top 10 causes of disability worldwide and the seventh cause of years of life lost to disability.6–8 In Canada, migraine is most common in women and most common between the ages of 30 and 49.9
Dr. Elizabeth Leroux, president of the Canadian Headache Society and founder of the websites Migraine Quebec and Migraine Canada, says the availability of AJOVY™ is good news for all migraine patients and treaters. "The unique dosing options that AJOVY™ offers will provide added flexibility and stability for many patients to manage their symptoms with less disruption to their lives and routines. This is a welcome next step in migraine management."
AJOVY™ was evaluated in two pivotal Phase III clinical trials that enrolled patients with disabling migraine and studied fremanezumab as a prophylactic treatment. In these trials, efficacy assessments included the change from baseline in the number of average monthly migraine or headache days and the proportion of patients achieving at least a 50% reduction in affected days. The safety profile was also assessed in these trials.1–3
About the AJOVY™ Teva Support Solutions® (AJOVY TSS) Patient Support Program
AJOVY™ patients and prescribers are supported by the AJOVY™ Teva Support Solutions® Patient Support Program, which was developed in collaboration with Canadian migraine experts and offers services such as injection training, insurance/coverage investigation, and paperwork assistance.
About AJOVY™
AJOVY™ (fremanezumab) is indicated for the preventive treatment of migraine in adults who have at least four migraine days per month. AJOVY™ is available as a 225 mg/1.5 mL single-dose injection in a prefilled syringe with two dosing options: 225 mg monthly, administered as one subcutaneous injection; or 675 mg every three months (quarterly), administered as three subcutaneous injections. AJOVY™ is intended for patient self-administration after the patient or their caretaker has been trained to administer the product.
Helping improve the lives of Canadians
At Teva, we are committed to providing innovative and quality medicines to the nearly 200 million people we serve around the world every day. From our role as a global leader in generic and brand name medicines to the innovative solutions we create for our healthcare partners, we offer a unique perspective on health—here in Canada and around the world.
About Teva Canada
Teva Canada, headquartered in Toronto, has provided affordable healthcare solutions to Canadians for over 50 years, building their trust one prescription at a time with now more than 217,00010 prescriptions filled each day with our products. Originally Novopharm Limited, Teva Canada specializes in the development, production, and marketing of high-quality generic prescription pharmaceuticals and, through our branded division, focuses on a diverse line of innovative products in a variety of therapeutic areas. Teva Canada employs more than 900 professionals, had sales of nearly $1.3 billion10 in 2019, and markets more than 385 products in 1,000 SKUs10 in Canada. We are a proud subsidiary of Teva Pharmaceutical Industries Ltd. Learn more at www.tevacanada.com.
About Teva Pharmaceutical Industries Ltd.
Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) has been developing and producing medicines to improve people's lives for more than a century. We are a global leader in generic and specialty medicines with a portfolio consisting of over 3,500 products in nearly every therapeutic area. Around 200 million people around the world take a Teva medicine every day and are served by one of the largest and most complex supply chains in the pharmaceutical industry. Along with our established presence in generics, we have significant innovative research and operations supporting our growing portfolio of specialty and biopharmaceutical products. Learn more at www.tevapharm.com.
___________________________________________
CGRP: calcitonin gene-related peptide; SKU: Stock Keeping Unit
Dodick DW et al. Effect of fremanezumab compared with placebo for prevention of episodic migraine. JAMA. 2018;319(19):1999–2008. doi: 10.1001/jama.2018.4853.
3.
Silberstein SD et al. Fremanezumab for the preventive treatment of chronic migraine. N Engl J Med. 2017;377(22):2113–2122. doi: 10.1056/NEJMoa1709038.
4.
Buse DC, Rupnow MF, Lipton RB. Assessing and managing all aspects of migraine: migraine attacks, migraine-related functional impairment, common comorbidities, and quality of life. Mayo Clin Proc. 2009;84:422–435. doi: 10.1016/S0025-6196(11)60561-2.
5.
Lipton RB, Liberman JN, Kolodner KB, et al. Migraine headache disability and health-related quality-of-life: a population-based case-control study from England. Cephalalgia. 2003;23:441–450. doi: 10.1046/j.1468-2982.2003.00546.x.
Global Burden of Disease Study Collaborators. Global, regional, and national incidence, prevalence, and years lived with disability for 301 acute and chronic diseases and injuries in 188 countries, 1990–2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet. 2015;386:743–800. doi: 10.1016/S0140-6736(15)60692-4.
8.
Institute for Health Metrics and Evaluation. Global burden of disease visualization tools. Available from: http://vizhub.healthdata.org/gbd-compare/. Accessed January 2016.
9.
Ramage-Morin PL, Gilmour H. Prevalence of migraine in the Canadian household population. Health Rep. 2014;25(6):10–16.
10.
Source: IQVIA CDH & Compuscript MAT. April 2020.
SOURCE Teva Canada
Mitsubishi Tanabe Pharma Canada Announces That Treatment For Amyotrophic Lateral Sclerosis (ALS) Has Been Added to British Columbia Pharmacare Formulary
TORONTO, Aug. 19, 2020 /CNW/ - Mitsubishi Tanabe Pharma Canada, Inc. (MTP-CA), a subsidiary of Mitsubishi Tanabe Pharma America, Inc. (MTPA), announced today that RADICAVA® (edaravone), an infusion treatment for amyotrophic lateral sclerosis (ALS), is now listed on the British Columbia (BC) PharmaCare Formulary (special authorization).
"ALS is a rapidly progressive, neurodegenerative and fatal disease, and the listing of this therapy is an encouraging step for the ALS community," said Atsushi Fujimoto, President, MTP-CA. "We are very grateful to the Government of B.C. for providing access to eligible patients under its provincial PharmaCare Formulary."
In addition to the BC PharmaCare Formulary (special authorization), RADICAVA also is listed on the following:
Régie de l'assurance maladie du Québec (RAMQ) formulary (special authorization)
Ontario Drug Benefit Formulary (Exceptional Access Program)
Alberta Drug Benefit List (special authorization)
New Brunswick Drug Plan (NBDP) formulary (special authorization)
Manitoba Drug Benefits and Interchangeability Formulary (special authorization)
Saskatchewan Formulary (special authorization)
Nova Scotia Drug Formulary (special authorization)
MTP-CA continues to have discussions with other provinces, territories and federal agencies regarding the listing of RADICAVA under additional publicly funded drug programs.
About RADICAVA® (edaravone) RADICAVA (edaravone) is indicated to slow the loss of function in patients with amyotrophic lateral sclerosis (ALS), as measured by the ALS Functional Rating Scale - Revised (ALSFRSR).1 Edaravone was discovered and developed for ALS by Mitsubishi Tanabe Pharma Corporation (MTPC) through an iterative clinical development platform over a 13-year period. In 2015, edaravone was approved for use as a treatment for ALS in Japan and South Korea. RADICAVA was approved by the U.S. Food and Drug Administration in May of 2017. Marketing authorization was granted in Canada in October 2018 and Switzerland in January 2019.
About Mitsubishi Tanabe Pharma Canada, Inc. Based in Toronto, Mitsubishi Tanabe Pharma Canada, Inc. (MTP-CA) is a wholly-owned subsidiary of Mitsubishi Tanabe Pharma America, Inc. (MTPA) with a goal to provide therapies for some of the most difficult-to-treat diseases, including ALS. For more information, please visit www.mt-pharma-ca.com.
About Mitsubishi Tanabe Pharma America, Inc. Based in Jersey City, N.J., Mitsubishi Tanabe Pharma America, Inc. (MTPA) is a wholly-owned subsidiary of Mitsubishi Tanabe Pharma Corporation's (MTPC) 100 percent owned U.S. holding company, Mitsubishi Tanabe Pharma Holdings America, Inc. MTPA is dedicated to delivering innovative products that address the unmet medical needs of patients in North America. It was established by MTPC to commercialize approved pharmaceutical products in North America. For more information, please visit www.mt-pharma-america.com.
As a man starts to age, he needs to take better care of his mind and body. Even small lifestyle changes can make a big difference. Here are four tips for improving a man’s overall health.
Effectively Manage Stress
Research shows that stress can promote a number of serious ailments, including heart disease and high blood pressure. Depression is also more likely to occur. One of the best ways to help cope with stress is to get plenty of rest. Most men need at least seven hours of quality sleep a night. Upon awakening the next morning, you’ll feel energized and rejuvenated. It’s also a good idea to keep alcohol consumption to a minimum. When going through tough times, drinking alcohol only masks the underlying issue. Each day, set aside 30 minutes to meditate in a quiet place.
Eat Better
While you’re in high school, you can get away with eating pizza and fries every day. However, a poor diet is bound to catch up with you at some point. For starters, you need to start making healthy choices when grocery shopping. Avoid purchasing processed foods at all costs. Studies have proven that processed foods tend to be loaded with excess salt and sugar. Your best bet is to fill your shopping cart with as many fresh fruits and vegetables as possible. Although it’s safe to eat lean red meat, keep your consumption to around three servings a week.
Boost Your Testosterone
It’s not uncommon for a man’s testosterone levels to drop after turning 30 years of age. This hormone has a direct impact on sex drive and muscle growth. To help boost testosterone, develop a habit of working out a minimum of three days a week. Simple activities, like jogging and jumping rope, are sure to get your heart pumping. Exercising outdoors will also enable you to soak up extra sunlight, which triggers your body to produce more vitamin D. If your testosterone levels are still lower than normal, consider talking to a testosterone replacement therapy physician.
Drink Plenty of Water
Staying hydrated is essential for good health. Make it a priority to drink enough water throughout the day. If your urine looks yellow, this is a tell-tale sign that your body has become dehydrated. Sipping on smoothies will also help you to remain properly hydrated.
Now is the time to take control of your health. The first step is to get rid of your bad habits. After a while, your mind and body will start to feel stronger.
Corona-phobia, Facts, Fiction and Feelings
By Surgeon Charles Page, MD
Six months into the pandemic, there is hardly a sole on earth who isn’t in Coronavirus overload. What’s more, we don’t know what to believe! This is my attempt to intelligently discuss corona-phobias, facts, fiction, and feelings.
Q&A:
Doctor, can you give us the big picture of where we are in the Pandemic? Answer: We are now at 5.4 million cases in the United States. The total number of deaths is reaching 170,000. The Infection Fatality Rate, or IFR, is extremely low. Less than one half of one percent. THAT’S GOOD NEWS. When we compare this number projected six months ago of four to six percent, clearly things are not as bad as we predicted.
Comparing these numbers to other diseases such as 650,000 deaths per year from Heart Disease, and 500 deaths per year from cancer, it gives us another perspective. Hospitals are busy but not overwhelmed with COVID cases. At present, there does not seem to be any lack of resources. To my knowledge no one is having to take the old and sick off ventilators to make way for younger COVID patients. We’re busy, but not overwhelmed by lack of resources.
Can you give us your opinion on reinfection, vaccines, and new tests?
Answer: A new study on sailors showed no evidence of reinfection after previously contacting COVID. We are in phase 3 studies on the vaccines. Hopefully we’ll have a vaccine before the end of the year. SalivaDirect is a new $10 test, funded by the NBA and invented at Yale. It is easier, safer and quicker.
Can you tell us about what we are learning about treading COVID? Answer: We’re learning how to utilize our resources. Remdesivir, an antiviral, costs about 3000/dose and is being used in ICU’s only. Plasma, taken from COVID survivors, is being transfused for the really sick. Initially, most COVID patients were intubated early. Now we are learning to wait and try other measures--first.
We are still hearing two opposing COVID narratives among the scientific community. Isn’t Science supposed to be objective? Answer: Science is not as objective as we think. Everyone, including doctors and scientists, filters data through their worldview. We live in a culture of arbitrary absolutes, where those in power try to impose their relativistic assumption on the masses.
On one hand, the CDC rejects the new Henry Ford studies on Hydroxychloroquine, claiming they are not good (prospective, randomized) studies. On the other hand, they advocate—and impose--the wearing of masks. There are no definitive studies which show masks diminish the spread of COVID—especially in the community.
Doesn’t the kind of mask you wear make a difference?
Answer: Yes. A recent study out of Duke University used lasers to evaluate the spread of respiratory droplets using different kinds of masks—N95, regular surgical masks, cloth masks and looser fabrics. The thinner masks fragmented the droplets into smaller ones, helping them to stay aerosolized in the air longer. THAT’S BAD. Once again, the studies show that masks sequester the respiratory droplets when people talk or cough.
Doctor, if things aren’t as bad what’s portrayed in the media, then, why the corona-phobia? Answer: If we’ve learned anything, we’ve learned that COVID 19 is unpredictable. I think this goes beyond a political battle. What’s more, it’s become a legal issue. Hospital administrators, School boards, and business owners are placed in a no-win situation. Everyone knows its not as bad as we anticipated. The ‘game’ now revolves around mitigating risk. Ponder this: Leaders are trying to cover the bases of if and when they will encounter a lawsuit.
Charles Page is a Texas-based surgeon and author of several faith-based books. One of which is A Spoonful of Courage for the Sick and Suffering.
Dr. Page has been called the best guy to see on the worst day of your life. A surgeon from Texas, his latest book is "A Spoonful of Courage for the Sick and Suffering."
Deep Flavors Makes Delicious Kosher Cuisine Accessible for Home Cooks
Dallas, TX, August 19, 2020 — If you love cooking kosher or simply enjoy trying new foods and creating memorable meals in your home kitchen, Deep Flavors: A Celebration of Recipes for Foodies in a Kosher Style from Kenneth M. Horwitz offers an abundance of tempting dishes designed for cooks, whether Kosher or non-Kosher, with helpful tips for proper preparation.
“Cooking is worth some effort and attention to detail,” Horwitz writes. “The positive reactions from family or guests, as well as your own enjoyment, will make it worthwhile.”
“Effort” and “attention to detail,” however, don’t have to equate with “difficult.” In fact, throughout Deep Flavors, Horwitz shares his wisdom for sourcing ingredients and breaking recipes into simple steps — and how to do some of this prep work well in advance so that delicious meals can be served in spite of hectic schedules.
Between the covers of Deep Flavors, Horwitz offers an eclectic menu that includes traditional Jewish dishes plus other regional and international favorites reinterpreted to observe some or all of the rules for kosher foods. The result is a diverse anthology of recipes that will appeal to broad audiences everywhere — Jewish and otherwise.
Horwitz, a CPA by trade, explained in an interview with Today’s CPA that, “My approach to cooking is really an extension of what I do in my professional practice. I solve problems. One of the ‘problems,’ at least in my house, is that since we maintain a kosher house, but eat eclectically, is how to convert recipes so that they are kosher …”
Horwitz’s Texas State Fair Blue Ribbon-winning Spinach/Mushroom Lasagna, for instance, is a completely original vegetarian lasagna accessible to Jews and vegetarians, with a unique twist on ingredients that gives it a complex flavor profile. Even recipes for classic foods such as brisket and roast turkey contain newly imagined taste combinations and techniques to elevate them while maintaining recognizable hallmarks of each dish. Another recipe that epitomizes the standard set by Horwitz, yet remarkably simple to execute, is the Dill French Toast: savory, unique, and delicious.
Horwitz’s ultimate goal was to create recipes that are easy to read and easily followed by any-one with a basic knowledge of cooking. He provides detailed instructions with enhanced explanations and alternatives, additive for both the novice and the more experienced cook.
A Readers’ Favorite reviewer, who gave Deep Flavors a 5-star rating, referred to the book as “… an essential addition to any cookbook fanatic's collection and to anyone who believes in spending the time and effort to make the ‘food’ experience a real work of art …”
With 51 years in a general tax and transaction practice as a CPA and lawyer, Ken Horwitz developed a creative and focused approach to finding and fixing problems — a skill that translates well to the development of and modification of recipes based on traditional family favorites but tailored to one’s personal tastes and dietary needs.
His professional drive and the care given to his work have earned him multiple awards, including the Honorary Fellow for a lifetime of distinguished service and the 2017 Chairperson of the Year by the Texas Society of CPAs. Currently residing in Dallas, Texas, Horwitz enjoys sharing his passion for cooking with his wife and his children’s families. Horwitz believes that one of the highest compliments he has received came from a longstanding client who uses numerous lawyers. He said, “Ken, you are the only lawyer we use whose work we have not had to fix.” Horwitz’s goal is for Deep Flavors to reach that same standard.
Deep Flavors Publisher: Inspire on Purpose ISBN-13: 978-1-941782-51-4 ISBN-10: 1-941782-51-5 Available from Amazon.com
###
Back at it again with another Podcast for you guys! This week I discuss my morning routine, small things for others and answer some of your questions from my instagram! Please subscribe, leave me a review and share this podcast! Happy Wednesday Train It Right Life Fam!
